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Article Information  ABSTRACT 
Received: 19th September 2020  Objective: The present study planned to study the combined effect of Bromelain and Turmeric in acetic 
acid-induced ulcerative colitis in Wistar rats. Methodology: Wistar rats of either sex (n = 30) were 
divided into 5 groups. Group – I, Sham control, administered a single dose of vehicle rectally; Group –
II, colitis control, colitis was induced by rectal administration of a single dose of 2 ml of 3%, v/v of 
acetic acid in 0.9% saline; Group–III, treated with Turmeric (50 mg/kg/p.o); Group–IV, treated with 
Bromelain (100 mg/kg/p.o) and Group –V, treated with both Turmeric (50 mg/kg/p.o) and Bromelain 
(100 mg /kg/p.o). Colitis was induced in all the treatment groups on the first day and drug treatment 
was continued for 7 days. During the treatment period, Disease Activity Index (DAI) was assessed daily 
and on the 8th day White Blood Cell (WBC) Count and Differential Leucocyte Count (DLC) was 
performed and on the 9th day, all the rats were sacrificed for the assessment of intestinal inflammation, 
colon myeloperoxidase (MPO) levels and, Histopathology. Results obtained were analyzed by one-way 
analysis of variance followed by Tukey’s multiple comparison test. Results: Overall changes in DAI, 
Inflammatory scores, WBC, DLC and, MPO have shown significant improvement with Turmeric and 
Bromelain compared to Colitis control. However, the combined therapy has shown to be more effective 
in alleviating ulcerative colitis compared to individual therapies. Conclusion: The present study 
recommends that the combination of Turmeric and Bromelain has a synergistic effect in treating 
ulcerative colitis. 
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Inflammatory bowel diseases (IBDs) are chronic inflammatory 
disorders of the gastrointestinal tract. The term IBD describes 
two specific diseases: ulcerative colitis (UC) and Crohn’s 
 
_______________________________________________________________________________________________ 





disease (CD) [1]. These disorders were first described by Sir 
Samuel Wilks and Doctor Crohn [2,3]. Ulcerative colitis is 
characterized by inflammation that starts in the rectum, spreads 
proximally to other regions of the colon and, sometimes involves 
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the peri-appendiceal region. Whereas, Crohn’s disease is 
characterized by inflammation, which is non-continuous and 
spreading across the gastrointestinal tract, most commonly the 
terminal ileum or the perianal region. It is commonly associated 
with complications such as strictures, abscesses and, fistulas [4].                                                                                                                 
 
The annual incidence of ulcerative colitis and Crohn's disease 
ranges from 1 to 10 cases per 100,000 people across different 
regions [5]. The incidence and prevalence of IBD are found to 
be high in industrialized nations in North America and Europe 
and have been increasing in recent years in previously low-
incidence areas such as Asia [6]. 
 
Although the exact etiology of the pathogenesis of ulcerative 
colitis is largely unknown, growing evidence specifies the 
involvement of multiple etiological factors such as an 
individual’s genetic susceptibility, external environment, 
intestinal microbial flora and, immune responses [7]. Though 
conventional treatments are effective in maintaining remission 
and decreasing the length of active disease periods, 
unfortunately, the long-term usages of these agents are reported 
to be associated with undesirable side effects and compromise 
the therapeutic advantage. Therefore, there is a need for the 
investigation of novel agents that are effective and safe for 
humans. Turmeric, a dry rhizome of Curcuma longa Linn 
(Zingiberaceae), has been used for centuries in indigenous 
medicine. Some of the recent studies revealed that curcumin, an 
active component of turmeric was found to be beneficial in 
preventing or ameliorating UC and inflammation [8]. The major 
problem associated with curcumin is its poor bioavailability due 
to its rapid metabolism in the liver and intestinal wall. Curcumin, 
therefore, could be a therapeutic option for the treatment of 
different diseases, provided limitations in its oral bioavailability 
can be overcome [9]. A Significant number of studies proved 
that adding bioavailability enhancer to curcumin enhanced its 
clinical effectiveness [10]. Studies are reporting the beneficial 
effect of bromelain in inflammatory conditions and also as a 
bioavailability enhancer [11,12]. 
 
Till now, no study has been done to investigate the effect of the 
combination of Turmeric and Bromelain in ulcerative colitis. 
Therefore, the present study was planned to investigate the 
combined effect of Bromelain and Turmeric in acetic acid-
induced ulcerative colitis using Wistar rats. The potential of 
treatments was evaluated by assessing disease activity index 
(DAI), ulcer index, WBC and DLC, myeloperoxidase (MPO), 
and histopathological studies. 
 
MATERIALS AND METHODS  
Chemicals 
WBC fluid and Agar-agar were purchased from S.D. Fine 
chemical Ltd. Leishman’s stain   
was purchased from NICE-Chemicals Pvt Ltd.   Hexadecyl 
trimethyl ammonium bromide and Orthodianisidine 
hydrochloride were purchased from Sigma Aldrich. Bromelain, 
Turmeric and, rectal catheters were purchased from local stores.  
 
Experimental Animals  
Wistar rats of either sex (150-250 g) were obtained from 
National Centre for Laboratory Animal Sciences, National 
Institute of Nutrition, Hyderabad, India. They were maintained 
under standard laboratory conditions (12-h light/dark cycle, 
25±3˚C, and 45-46% humidity) and provided with standard rat 
feed and water ad libitum.  All the rats were acclimatized to 
standard laboratory conditions for one week before starting the 
experiment.                                                             
All the experimental procedures were done following the 
“Committee for the Purpose of Control and Supervision of 
Experiments on Animals” (320/CPCSCEA dated 03-01 2001) 
guidelines. The study was reviewed and approved by the 
Institutional Animal Ethics Committee (GPRCP/IAEC), G. 
Pulla Reddy College of Pharmacy, Hyderabad, India.  
 
Experimental protocol                         
Rats were randomly allocated to five groups (n=6). Group – I, 
Sham control administered a single dose of vehicle rectally; 
Group –II, colitis control, colitis was induced by rectal 
administration of a single dose of 2 ml of 3%, v/v of acetic acid 
in 0.9% saline; Group–III, treated with Turmeric (50 mg/kg/p.o); 
Group–IV, treated with Bromelain (100 mg/kg/p.o) and Group 
–V, treated with both Turmeric (50 mg/kg/p.o) and Bromelain 
(100 mg /kg/p.o). Colitis was induced in all the treatment groups 
on the first day and drug treatment was continued for 7 days. 
During the treatment period Disease activity index (DAI) was 
assessed daily and on the 8th day the rats were anesthetized with 
Isoflurane and blood was collected by a retro-orbital puncture 
for WBC & DLC Count. On the 9th day animals were sacrificed 
by cervical dislocation (under Isoflurane anesthesia) and the 
colon was dissected out and flushed gently with saline and it was 
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used for macroscopic scoring, MPO estimation, and 
Histopathology.  
 
Induction of colitis  
The animals were fasted overnight with free access to water. On 
the next day, they were anesthetized and a rectal catheter with 2 
mm diameter was inserted through the rectum into the colon to 
a distance of 8 cm. A solution of 2 ml of acetic acid (3%, v/v) in 
0.9% saline was instilled into the lumen of the colon and 
maintained in a supine Trendelenburg position for 30 sec to 
prevent leakage [13]. 
 
Assessment of DAI score of colitis 
 Colitis was quantified with the DAI scoring system by assessing 
weight loss, stool consistency, and rectal bleeding on daily basis 
for 7 days during the treatment period in all groups (Table 1) 
[13]. 











No blood in 
hem occult 
1 1 - 5  
Pasty & semi-formed 




2 5 - 10  
Pasty & semi-formed 




3 10 – 20 
Pasty & semi-formed 




4 Above 20 
Liquid stools  that  did 




Estimation of WBC and Neutrophils 
Blood was collected on the 8th day through a retro-orbital 
puncture and collected into sample tubes coated with EDTA. 
Blood sample from the tube was drawn up to the 0.5 mark on the 
WBC pipette and, then mixed with WBC diluting fluid up to 
mark 11  and allowed for 10 min for then erythrocytes to lyse. 
Thereafter, the Neubauer counting chamber was filled with the 
diluted sample and WBC was counted microscopically under 40 
x magnification. The total numbers of white cells in the 4 large 
squares are counted and at the end, the total white cell count. 
WBC is calculated from the formula, 
𝑊𝑊𝑊𝑊𝑊𝑊 = 𝑛𝑛 × 20 × 2.5 
where n is the number of cells counted. The dilution factor is 
1:20 and the volume factor for the counting chamber is 1/0.4 (i.e. 
2.5). 
The Leishman staining technique was used for the estimation of 
neutrophil count. A drop of blood was placed on one end of the 
glass slide. The coverslip was used to make a blood smear on the 
glass slide using the push wedge technique. The Leishman was 
applied on the blood film and then left to stand for 2 min. 
Thereafter, distilled water, two times the quantity of stain was 
used to flood the thin film of the blood; the setup was mixed 
gently for 2 min and then allowed to stand for 15 min before 
rinsing the stain. The slide was left to dry and counting was done 
on the microscope under oil immersion using 100x 
magnification [14]. 
 
Assessment of macroscopic characters 
The animals were sacrificed and the colon was excised and 
opened longitudinally. Macroscopic scoring was done using the 
following score criteria, 0 - No change in both mucosa and 
serosa, 1- Petechial bleeding and hyperemia, 2-single mucosal 
erosion or ulceration, 3- single mucosal erosion or ulcer with 
hyperemic, adhesive, or hemorrhagic lesions in the serosa and 
mesentery, 4-multiple erosions or ulcerations (less than 10 cm) 
and 5-Multiple erosions or ulcerations (more than 10 cm) [15]. 
 
Estimation of colonic MPO level 
The colon was taken, weighed (500mg) and, rinsed with ice-cold 
saline. Then it was blotted dry, weighed and, minced. The 
minced tissue was homogenized in 10 volumes of ice-cold 
potassium phosphate buffer (pH 7.4) using a Remi tissue 
homogenizer. The homogenate was centrifuged at 3500 rpm for 
30 min at 4°C. The supernatant was discarded.  
 
The pellet was collected and 10 ml of ice-cold 50 mM potassium 
phosphates buffer (pH 6.0) containing 0.5% hexadecyl trimethyl 
ammonium bromide and 10 mM ethylene diamine tetra-acetic 
acid was added. It was then subjected to one cycle of freezing 
and thawing and subjected to sonication for 15 seconds. The 
resulting solution was centrifuged at 15,000 rpm for 20 min. 
From this 0.1 ml of supernatant was taken added with 2.9 ml of 
50 mM phosphate buffer containing 0.167 mg/ml O-dianisidine 
hydrochloride and 0.0005% H2O2. The change in absorbance 
was measured spectrophotometrically at 460 nm. One unit of 
MPO activity is defined as the change in absorbance per minute 
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by 1.0 at room temperature in the final reaction. MPO activity is 






𝑤𝑤𝑤𝑤𝑎𝑎𝑔𝑔ℎ𝑎𝑎 𝑜𝑜𝑜𝑜 𝑎𝑎ℎ𝑤𝑤 𝑝𝑝𝑎𝑎𝑤𝑤𝑎𝑎𝑤𝑤 𝑜𝑜𝑜𝑜 𝑎𝑎𝑎𝑎𝑡𝑡𝑡𝑡𝑡𝑡𝑤𝑤 𝑎𝑎𝑎𝑎𝑡𝑡𝑤𝑤𝑛𝑛 
 
Where X = 10 X changes in absorbance per minute / Volume of 
supernatant taken in the final reaction [15]. 
 
Histopathology 
A small segment of the colon was fixed in phosphate-buffered 
formaldehyde and embedded in paraffin. Tissue sections of 5μm 
were prepared, stained with hematoxylin and eosin and, were 
evaluated by light microscopy [15]. 
 
Statistical analysis 
Results were expressed as Mean ± S.E.M. The statistical 
significance was assessed using “One way Analysis of 
Variance” (ANOVA) followed by Tukey’s multiple comparison 
test using Graph pad prism 7.0 software.  P < 0.05 was 
considered significant.  
 
RESULT AND DISCUSSION 
Effect of Bromelain and Turmeric on Disease Activity Index 
(DAI) 
As shown in Figure 1, the DAI scores reflect the highest 
incidence of weight loss, diarrhea and, rectal bleeding in the 
colitis control group compared to the sham control group (p< 
0.0001), whereas treatment with Turmeric (p<0.005) and 
Bromelain (p<0.01) alone has significant improvement in DAI 
scores as compared to the colitis control group. However, the 
combination of Bromelain and Turmeric has shown highly 
significant improvement in DAI scores, resuming to basal scores 
(p< 0.0001). Results are expressed as Mean± S.E.M ,  P < 
0.0001 vs. Sham control. aP < 0.005, bP < 0.01, cP < 0.0001 vs. 
Colitis control  #P < 0.02 vs. Combination. 
 
Figure 1:  Effect of Bromelain and Turmeric on DAI 
Effect of Bromelain and Turmeric on WBC and neutrophil 
count 
Table 2: Effect of Bromelain and Turmeric on WBC and 
Neutrophil count. 
Groups ( n=6) 
WBC Count 
(cells / mm3 ) 
Neutrophil   count 
(%) 
Sham control 6558 ± 328.2 57 ± 1.528 
Colitis control 12700 ± 186.6α 76.67 ± 1.145α 
Turmeric  8058 ± 253.1a # 58.67 ± 1.994a 
Bromelain  7250 ± 246.0a 55.17± 1.6a 
Combination 6575 ±182.5a 55.17 ± 1.797a 
Results are expressed as Mean± S.E.M , α P < 0.0001 vs. Sham 
control. a P < 0.0001 vs. Colitis control. #P < 0.002 vs. 
Combination. 
Induction of colitis has significantly increased WBC count in the 
colitis control group compared to the sham control group (P < 
0.0001). Treatment with turmeric and bromelain alone has 
shown a significant decrease in WBC count compared to the 
colitis control group (P < 0.0001). A More significant decrease 
was shown upon treating with the combination of bromelain and 
turmeric (P < 0.002) compared to individual treatments and also 
resumed to basal levels. Colitis induction significantly increased 
neutrophil count in the colitis control group compared to the 
sham control group (P < 0.0001). Upon treatment with Turmeric 
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and Bromelain alone has shown a significant decrease in 
neutrophils compared to the colitis control group (P < 0.0001), 
and there was no significant decrease in neutrophil count upon 
treating with the combination [Table 2]. 
 
Effect of Bromelain and Turmeric on Macroscopic Scoring 
Induction of colitis significantly increased the macroscopic 
score in the colitis control group compared to the sham control 
group (P < 0.0001). Treatment with Turmeric and Bromelain 
alone has shown a significant decrease in macroscopic scoring 
(P < 0.0001) and treating with the combination of Turmeric and 
Bromelain has shown a significant reduction in the macroscopic 





Figure 2: Macroscopic Scoring for Colon 
Macroscopic presentation of acetic acid-induced ulcerative colitis in rats. A: Sham control, B: Colitis control treated with acetic 
acid rectally, C: UC treated with Turmeric (50 mg/kg), D: UC treated with Bromelain (100 mg/kg), E: UC treated with 
Combination of Bromelain (100 mg/kg) and Turmeric (50 mg/kg). 
 
 
Figure 3: Effect of Bromelain and Turmeric on Macroscopic Scoring. 
Results are expressed as Mean± S.E.M,  P < 0.0001 vs. Sham control. aP < 0.0001 vs. Colitis control. #P < 0.002 vs. Combination. 
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Effect of Bromelain and Turmeric on Colonic MPO  
Induction of colitis has significantly increased the colonic MPO 
levels in the colitis control group compared to the sham control 
group (P < 0.0001). Treatment with Turmeric and Bromelain 
alone has shown a significant decrease in MPO levels compared 
to the colitis control group (P < 0.0001). The combination of 
both turmeric and bromelain has shown a more significant 
reduction in MPO levels compared to monotherapies (P < 0.002) 
[Figure 4].  
 
Effect of Bromelain and Turmeric on Histopathology 
Sham control (A) showed normal muscularis mucosa, the 
submucosa and, the mucosa with normal epithelial lining of the 
crypts, the goblet cells and, the lamina propria. Colitis control 
(B) showing the disruption of the epithelial mucosa layer of the 
villi with necrotic material in the lumen. Turmeric (50 mg/kg) 
(C)   attenuated the extent and severity of the histological signs 
of cell damage.  
 
Bromelain (100 mg/kg) (D) showed mild histological signs of 
cell damage. Combination (Turmeric 50 mg/kg and Bromelain 
100 mg/kg) (E) showed intact epithelial lining with normal 
muscularis mucosa, the submucosa and, the mucosa [Figure 5]. 
 
 
Figure 4: Effect of Bromelain and Turmeric on MPO levels 
Results are expressed as Mean ± S.E.M,  P < 0.0001 vs. Sham control. aP < 0.0001 vs. Colitis control #P < 0.0001, $P < 0.002 vs. 
Combination. 
 
Figure 5: Showing 5µ thick Haemotoxylin & Eosin stained section of the rat colonic tissue under 10X magnification. 
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Inflammatory bowel disease is a chronic inflammatory disease 
of the gastrointestinal tract characterized by frequent diarrhea, 
abdominal pain, bleeding, anemia, weight loss and, chronic 
recurrent ulceration of the bowel. Causative agents are stress, 
diet, smoking and, microbial factors, which may lead to the 
development of carcinoma if untreated [16]. 
 
A recent study reported that “At the turn of the 21st century, 
inflammatory bowel disease has become a global disease with 
accelerating incidence in newly industrialized countries whose 
societies have become more westernized. Although the 
incidence is stabilizing in western countries, the burden remains 
high as prevalence surpasses 0·3%. These data highlight the 
need for research into the prevention of inflammatory bowel 
disease and innovations in health-care systems to manage this 
complex and costly disease” [17]. 
 
The main aim of the treatment of UC is to eliminate symptoms, 
prevent flare-ups (maintain long-term remission) and restore 
quality of life. The allopathic drugs presently available for the 
treatment of UC are used mainly to reduce infection and 
inflammation. They include aminosalicylates, anti-
inflammatory steroids, corticosteroids, immunosuppressants 
and, TNF (Tumour Necrosis Factor) inhibitors. However, side 
effects associated with these drugs are paramount and search is 
on for newer agents as well as for evidence based use of herbal 
medications [18].  
 
Turmeric is a medicinal plant extensively used in Ayurveda, 
Unani and Siddha systems of medicine and is also used as a 
home remedy for various diseases. Curcumin, the main yellow 
bioactive component of turmeric has been found to have a broad 
spectrum of biological actions; anti-inflammatory, antioxidant, 
anticarcinogenic, Antimutagenic, anticoagulant, antibacterial, 
antifungal, antiulcer, etc. However, one of the major limitations 
with ingesting curcumin is its poor bioavailability, which 
appears to be primarily due to poor absorption, rapid 
metabolism, and rapid elimination. Several strategies have been 
investigated to improve curcumin’s bioavailability [19]. 
 
Bromelain is a complex natural mixture of proteolytic enzymes 
derived from pineapple (Ananas cosmosus) and found to exhibit 
several therapeutic properties, it is also used as a nutritional 
supplement to promote health. It is reported to enhance 
bioavailability and reduces the side effects that are associated 
with various antibiotics Furthermore, bromelain is reported to 
possess an immunomodulator, anti-metastatic, anti-edematous, 
anti-thrombotic and anti-inflammatory actions, etc [20,21].  
 
Bromelain and Turmeric have been successfully used alone to 
reduce the swelling of the inflammation. Recent investigations 
have been proved that combined therapies are more effective 
than monotherapies. Moeinian M et al.,2014  have reported the 
priority of the combination of butyrate, L.casei and, L-carnitine 
in ameliorating the severity of colitis in comparison to 
monotherapies [22]. So the present study was planned to 
investigate the combined effect of bromelain and turmeric in 
acetic acid-induced Ulcerative colitis. 
 
Acetic acid-induced ulcerative colitis has been found to have 
morphological similarities with the human disease of ulcerative 
colitis and also it is a standard reproducible model for UC, 
wherein inflammatory mediators such as reactive oxygen 
species, eicosanoids play a significant role. The underlying 
pathophysiological mechanisms involved in this include 
mucosal barrier destruction by chemical stimulation, enhanced 
vessel permeability, increased inflammatory mediators, etc [23]. 
 
Based on the clinical symptoms of UC like bloody stools, weight 
loss, Diarrhea, the scoring system is developed to assess the 
severity of the disease. In the present study colonic 
administration of 3% v/v acetic acid has shown induction of UC, 
as this significantly increased DAI score in the colitis control 
group compared to the sham control group. Upon treatment for 
7 days with Turmeric & Bromelain has significantly decreased 
DAI score compared to the colitis control group, also there is a 
significant decrease in DAI score in the combination group 
compared to individual therapies. 
   
UC involves the activation of the Immune system and migration 
of activated neutrophils. Migration and accumulation of WBC & 
Neutrophils to the inflamed intestinal mucosa is a prominent 
feature in ulcerative colitis [24]. This can be evaluated by 
measuring WBC & neutrophil count.  Induction of colitis has 
significantly increased WBC count in colitis control compared 
to the sham control group. Treatment with turmeric and 
bromelain alone has shown a significant decrease in WBC count 
compared to the colitis control group and a more significant 
decrease in WBC count was observed upon treating with the 
combination compared to monotherapies.  
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 A Significant increase in neutrophils count was observed in 
colitis control compared to the sham control group. Upon 
treatment with Turmeric and Bromelain alone and the 
combination has shown a significant decrease in neutrophils 
compared to the colitis control group, and no significant 
difference was observed in neutrophils count upon treating with 
the combination compared to monotherapies. Fitzhugh DJ et al 
demonstrated that bromelain can effectively decrease neutrophil 
migration to sites of acute inflammation [25]. 
 
 The severity of the Ulcer was evaluated by a macroscopic 
scoring system [15]. Induction of colitis significantly increased 
ulcer score in colitis control compared to the sham control group. 
Treatment with Turmeric and Bromelain alone has shown a 
significant decrease in Ulcer Index compared to the colitis 
control group and upon treatment with the combination has 
shown a more significant reduction in the Ulcer score compared 
to monotherapies. 
 
Myeloperoxidase (MPO), a component of monocyte and 
neutrophil granules, is used clinically as a marker of neutrophil 
infiltration into the intestinal mucosa. Curcumin has been shown 
to decrease intestinal inflammatory disease-associated MPO 
activity in animal models of colitis. In an immune-mediated 
model of mouse colitis, Mouzaoui et al. demonstrated that 
curcumin is capable of reducing neutrophil intestinal infiltration, 
thereby reducing MPO activity, as well as returning NO levels 
to baseline via inhibition of iNOS and reduced inflammatory cell 
infiltration [26]. In a rat model of TNBS-colitis, it has been 
investigated that treatment with curcumin significantly reduced 
the activity of MPO. Similarly, in a rat methotrexate-colitis 
model, curcumin decreased intestinal MPO and increased levels 
of free radical-scavenging superoxide dismutase [27,28]. 
 
Myeloperoxidase is an hemoenzyme, which is released from 
neutrophils to eradicate pathogens. Therefore, activated 
neutrophils may contribute to tissue damage at sites of 
inflammation. Induction of colitis has significantly increased the 
colonic MPO levels in colitis control compared to the sham 
control group. Treatment with Turmeric and Bromelain alone 
and combination groups have shown a significant decrease in 
MPO levels compared to the colitis control group. However, no 
significant difference was observed in MPO levels of the 
combination compared to monotherapies.  
In ulcerative colitis, mucosal healing may remain the ultimate 
therapeutic goal, because the disease is limited to the mucosa. 
The progression of inflammation in UC is associated with 
several mucosal changes, vascular congestion, erythema, and 
granularity. As the inflammation becomes more severe, 
spontaneous bleeding, erosions and, ulcers develop. An 
International Organization of Inflammatory Bowel Disease 
(IOIBD) task force defined mucosal healing in UC as the 
absence of friability, blood, erosions, and ulcers in all sections 
of the colonic mucosa [29]. 
 
In Histological findings such as mucosal edema, disruption of 
the epithelial mucosal layer of the villi and necrosis of the colon 
is considered a reliable sensitivity indicator of the severity and 
extent of inflammatory response [1]. Sham control showed 
normal muscularis mucosa, the submucosa and, the mucosa with 
normal epithelial lining of the crypts, the goblet cells and, the 
lamina propria. Whereas, Colitis control (acetic acid-induced) 
showing the disruption of the epithelial mucosa layer of the villi 
with necrotic material in the lumen and Turmeric (50 mg/kg) 
group attenuated the extent and severity of the histological signs 
of cell damage, Bromelain(100 mg/kg) showed mild histological 
signs of cell damage and  Combination – (Turmeric 50 mg/kg 
and Bromelain 100 mg/kg) showed intact epithelial lining with 
normal musularis mucosa, the submucosa and, the mucosa. 
 
CONCLUSION 
The findings of the present study clearly show that the 
combination of Bromelain and Turmeric has significantly 
suppressed the DAI score by increasing body weight and 
decreasing stool consistency, rectal bleeding compared to 
individual therapies. The combination of Turmeric and 
Bromelain has shown a significant reduction in macroscopic 
scoring, ulcer index compared to individual therapies. A 
significant change was observed in WBC, DLC Count and, MPO 
levels in individual and combination groups compared to the 
colitis group but no significant difference was observed in the 
case of the combination compared to monotherapies. While both 
of these herbs complement each other and they have been 
successfully used alone to reduce the inflammation in UC, and 
so on combination therapy has proved more effective compared 
to monotherapies, the present study suggests that combined 
action of bromelain and turmeric is more effective in reducing 
the inflammation in ulcerative colitis. Further studies are 
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required to investigate the mechanism involved in the synergistic 
effect of Bromelain and Turmeric Combination. 
 
FINANCIAL ASSISTANCE  
Nil 
 
CONFLICT OF INTEREST  
The authors declare no conflict of interest. 
 
AUTHOR CONTRIBUTION 
A. Lalitha Devi, Y. Sree Hari and, Abdul Samad designed the 
work and made necessary corrections and, revisions in the 
manuscript.  K. B. Keerthana collected the content and 
performed the literature review and also contributed to writing 
the manuscript. All the authors drafted the final manuscript. R. 
Padmavathi supervised the work and involved in designing and 
conducting experimental work, preparation of manuscript 
 
REFERENCES  
[1] Langner C, Magro F, Driessen A, Ensari A, Mantzaris GJ, 
Villanacci V, Becheanu G, Borralho Nunes P, Cathomas G, 
Fries W, Jouret-Mourin A, Mescoli C, De Petris G, Rubio 
CA, Shepherd NA, Vieth M, Eliakim R, Geboes K. The 
histopathological approach to inflammatory bowel disease: 
A practice guide, Springer Verlag, 2014. 
[2] Wilks S, Moxon W. Lectures on Pathological Anatomy. 
LANE Libr., 733 (1875). 
[3] Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: 
A pathologic and clinical entity. J. Am. Med. Assoc., 99, 
1323–9 (1932). 
[4] Liu TC, Stappenbeck TS. Genetics and Pathogenesis of 
Inflammatory Bowel Disease. Annu. Rev. Pathol. Mech. 
Dis., 11, 127–48 (2016). 
[5] Solanki R, Madat D, Chauhan K, Parmar L. Recent 
approaches in pathogenesis of inflammatory bowel disease, 
2010. 
[6] Su HJ, Chiu YT, Chiu CT, Lin YC, Wang CY, Hsieh JY, 
Wei SC. Inflammatory bowel disease and its treatment in 
2018: Global and Taiwanese status updates. J. Formos. 
Med. Assoc., 118, 1083–92 (2019). 
[7] Zhang, Yi-Zhen, and Yong-Yu Li. Inflammatory bowel 
disease: pathogenesis. World journal of gastroenterology: 
WJG 20, no. 1,91 (2014). 
[8] Baliga MS, Joseph N, Venkataranganna M V., Saxena A, 
Ponemone V, Fayad R. Curcumin, an active component of 
turmeric in the prevention and treatment of ulcerative 
colitis: Preclinical and clinical observations. Food Funct., 
3, 1109–17 (2012). 
[9] Ma Z, Wang N, He H, Tang X. Pharmaceutical strategies of 
improving oral systemic bioavailability of curcumin for 
clinical application. J. Control. Release, 316, 359–80 
(2019). 
[10] Chakraborty M, Bhattacharjee A, Kamath JV. 
Cardioprotective effect of curcumin and piperine 
combination against cyclophosphamide-induced 
cardiotoxicity. Indian J. Pharmacol., 49, 65–70 (2017). 
[11] Hale LP, Greer PK, Trinh CT, Gottfried MR. Treatment 
with oral bromelain decreases colonic inflammation in the 
IL-10-deficient murine model of inflammatory bowel 
disease. Clin. Immunol., 116, 135–42 (2005). 
[12] Zhou Z, Wang L, Feng P, Yin L, Wang C, Zhi S, Dong J, 
Wang J, Lin Y, Chen D, Xiong Y, Peng J. Inhibition of 
epithelial TNF-α receptors by purified fruit bromelain 
ameliorates intestinal inflammation and barrier dysfunction 
in colitis. Front. Immunol., 8, (2017). 
[13] Thippeswamy BS, Mahendran S, Biradar MI, Raj P, 
Srivastava K, Badami S, Veerapur VP. Protective effect of 
embelin against acetic acid induced ulcerative colitis in rats. 
Eur. J. Pharmacol., 654, 100–5 (2011). 
[14] Kottke-Marchant K, Davis BH. Laboratory Hematology 
Practice. Wiley-Blackwell, (2012). 
[15] Patil NR, Rasal VP, Malabade RH. Screening of mandarin 
oil on indomethcin induced inflammatory bowel disease in 
wistar rats. Indian J. Pharm. Educ. Res., 48, 1–6 (2014). 
[16] Guan Q. A Comprehensive Review and Update on the 
Pathogenesis of Inflammatory Bowel Disease. J. Immunol. 
Res., 2019, (2019). 
[17] Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, 
Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan 
FKL, Sung JJY, Kaplan GG. Worldwide incidence and 
prevalence of inflammatory bowel disease in the 21st 
century: a systematic review of population-based studies. 
Lancet, 390, 2769–78 (2017). 
[18] Tabassum N, Hamdani M, Hussain Najar I. BRITISH 
BIOMEDICAL BULLETIN Original Natural Treatment for 
Inflammatory Bowel Disease, 2013. 
[19] Hewlings S, Kalman D. Curcumin: A Review of Its Effects 
on Human Health. Foods, 6, 92 (2017). 
[20] Pavan R, Jain S, Shraddha, Kumar A. Properties and 
Therapeutic Application of Bromelain: A Review. 
Biotechnol. Res. Int., 2012, 1–6 (2012). 
Journal of Applied Pharmaceutical Research 9 (2); 2021: 15 – 24 Padmavathi et. al  
 
 
  Journal of Applied Pharmaceutical Research (JOAPR)| April – June 2021 | Volume 9 Issue 2 |   24 
[21] Rathnavelu V, Alitheen NB, Sohila S, Kanagesan S, 
Ramesh R. Potential role of bromelain in clinical and 
therapeutic applications (Review). Biomed. Reports, 5, 
283–8 (2016). 
[22] Moeinian M, Ghasemi-Niri SF, Mozaffari S, Abdolghaffari 
AH, Baeeri M, Navaea-Nigjeh M, Abdollahi M. Beneficial 
effect of butyrate, Lactobacillus casei and L-carnitine 
combination in preference to each in experimental colitis. 
World J. Gastroenterol., 20, 10876–85 (2014). 
[23] Fabia R, Willen R, Arrajab A, Andersson R, Ahren B, 
Bengmark S. Acetic acid-induced colitis in the rat: A 
reproducible experimental model for acute ulcerative 
colitis. Eur. Surg. Res., 24, 211–25 (1992). 
[24] Sartor RB. Mechanisms of disease: Pathogenesis of Crohn’s 
disease and ulcerative colitis. Nat. Clin. Pract. 
Gastroenterol. Hepatol., 3, 390–407 (2006). 
[25] Fitzhugh DJ, Shan S, Dewhirst MW, Hale LP. Bromelain 
treatment decreases neutrophil migration to sites of 


























[26] Mouzaoui S, Rahim I, Djerdjouri B. Aminoguanidine and 
curcumin attenuated tumor necrosis factor (TNF)-α-induced 
oxidative stress, colitis and hepatotoxicity in mice. Int. 
Immunopharmacol., 12, 302–11 (2012). 
[27] Jiang H, Deng CS, Zhang M, Xia J. Curcumin-attenuated 
trinitrobenzene sulphonic acid induces chronic colitis by 
inhibiting expression of cyclooxygenase-2. World J. 
Gastroenterol., 12, 3848–53 (2006). 
[28] Song WB, Wang YY, Meng FS, Zhang QH, Zeng JY, Xiao 
LP, Yu XP, Peng D dan, Su L, Xiao B, Zhang ZS. Curcumin 
protects intestinal mucosal barrier function of rat enteritis 
via activation of MKP-1 and attenuation of p38 and NF-κB 
activation. PLoS One, 5, (2010). 
[29] Walsh A, Palmer R, Travis S. Mucosal healing as a target 
of therapy for colonic inflammatory bowel disease and 
methods to score disease activity. Gastrointest. Endosc. 
Clin. N. Am., 24, 367–78 (2014). 
 
